Macular Pigment Distribution as Prognostic Marker for Disease Progression in Macular Telangiectasia Type 2
نویسندگان
چکیده
منابع مشابه
Macular pigment distribution in Stargardt macular disease.
PURPOSE To investigate macular pigment optical density (MPOD) and distribution in patients with Stargardt disease. METHODS Prospective observational case series. The study included 13 eyes of 13 consecutive patients. A modified confocal scanning laser ophthalmoscope (SLO, Heidelberg, Germany) was used for MPOD measurement. It calculated the MPOD at 0.5° of the center of the fovea, and MPOD in...
متن کاملMacular telangiectasia type 2
Macular telangiectasia type 2 is a bilateral disease of unknown cause with characteristic alterations of the macular capillary network and neurosensory atrophy. Its prevalence may be underestimated and has recently been shown to be as high as 0.1% in persons 40 years and older. Biomicroscopy may show reduced retinal transparency, crystalline deposits, mildly ectatic capillaries, blunted venules...
متن کاملWhen is macular edema not macular edema? An update on macular telangiectasia type 2☆
Macular telangiectasia type 2 (Mac Tel 2) also known as idiopathic perifoveal telangiectasia and juxtafoveolar retinal telangiectasis type 2A is an enigmatic disease of unknown etiology. It manifests both neurodegenerative and vasculopathic characteristics. It manifests itself during the fifth or sixth decades of life. Clinical characteristics include minimally dilated parafoveal capillaries wi...
متن کاملAnalysis of candidate genes for macular telangiectasia type 2
PURPOSE To find the gene(s) responsible for macular telangiectasia type 2 (MacTel) by a candidate-gene screening approach. METHODS Candidate genes were selected based on the following criteria: those known to cause or be associated with diseases with phenotypes similar to MacTel, genes with known function in the retinal vasculature or macular pigment transport, genes that emerged from express...
متن کاملIntravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia
OBJECTIVES To evaluate the efficacy of intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia (IMT). MATERIALS AND METHODS Six eyes of 5 patients with type 2 IMT who received intravitreal bevacizumab between 2009 and 2014 were included in this study. All the patients had an ophthalmological examination including best corrected visual acuity (BCVA), dilated fundus exami...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Ophthalmology
سال: 2018
ISSN: 0002-9394
DOI: 10.1016/j.ajo.2018.07.017